According to the National Cancer Institute, approximately 18 million people are diagnosed with cancer in the U.S. every year. Yet despite this, the main therapies used to treat cancer are now more than 80 years old, with chemotherapy first becoming widely used in the 1940s, and radiation dating as far back as 1895. That appears to be changing in recent years, as innovative immuno-oncology companies look to therapies that harness the body's natural defense system. Including one Nasdaq-listed company developing a new technology that
"supercharges" the body's own Natural Killer (NK) cells to destroy tumors... And with virtually no side effects. In a Phase 1 clinical trial, the company's cutting edge approach demonstrated reductions in cancer cells as high as 63%. And more recent pre-clinical tests with second-generation therapies have seen even better results. Most important for investors, this company's market cap is still only $28 million. In contrast, Fate Therapeutics, which markets a therapy based on this same doctor's earlier research, has a market cap of $1.83 billion. That gives this under $2 Nasdaq a lot of room to grow. Access your full report to learn more about this developing story.
Market Tactic  | 
没有评论:
发表评论